Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Pioneer Pharma Completes $2.5 Million Investment in NovaBay

publication date: Nov 5, 2012
Pioneer Pharma, a Singapore company that is affiliated with Naqu Area Pioneer Pharma of Shanghai, completed a $2.5 million investment into California-based NovaBay® Pharma. The investment was part of deal that gives Pioneer the right to market NovaBay’s anti-infective wound-cleaning product, NeutroPhase, in China and Southeast Asia. The investment purchased two million units at a price of $1.25 each. Each unit consists of one share of NovaBay and a warrant to buy an additional share at a price of $1.50. NovaBay is currently trading at $1.31. More details....

Stock Symbol: (NYSE: NBY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here